help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Platet, N.
Right arrow Articles by Garcia, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Platet, N.
Right arrow Articles by Garcia, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Breast Cancer
Hazardous Substances DB
*ESTRADIOL
Molecular Endocrinology 14 (7):999
Copyright © 2000 by The Endocrine Society

Unliganded and Liganded Estrogen Receptors Protect against Cancer Invasion via Different Mechanisms

Nadine Platet, Séverine Cunat, Dany Chalbos, Henri Rochefort and Marcel Garcia

Institut National de la Santé et de la Recherche Médicale Unité Hormones et Cancer (U148) and Université de Montpellier I Montpellier, France 34090

While estrogens are mitogenic in breast cancer cells, the presence of estrogen receptor {alpha} (ER{alpha}) clinically indicates a favorable prognosis in breast carcinoma. To improve our understanding of ER{alpha} action in breast cancer, we used an original in vitro method, which combines transient transfection and Matrigel invasion assays to examine its effects on cell invasiveness. ER{alpha} expression in MDA-MB-231 breast cancer cells reduced their invasiveness by 3-fold in the absence of hormone and by 7-fold in its presence. Integrity of hormone and DNA-binding domains and activating function 2 were required for estradiol-induced inhibition, suggesting that transcriptional activation of estrogen target genes was involved. In contrast, these domains were dispensable for hormone-independent inhibition. Analysis of deletion mutants of ER{alpha} indicated that amino acids 179–215, containing the N-terminal zinc finger of the DNA-binding domain, were required for ligand-independent receptor action. Among different members of the nuclear receptor family, only unliganded ER{alpha} and ERß reduced invasion. Calreticulin, a Ca2+-binding protein that could interact with amino acids 206–211 of ER{alpha}, reversed hormone-independent ER{alpha} inhibition of invasion. However, since calreticulin alone also inhibited invasion, we propose that this protein probably prevents ER{alpha} interaction with another unidentified invasion-regulating factor. The inhibitor role of the unliganded ER was also suggested in three ER{alpha}-positive cell lines, where ER{alpha} content was inversely correlated with cell migration. We conclude that ER{alpha} protects against cancer invasion in its unliganded form, probably by protein-protein interactions with the N-terminal zinc finger region, and after hormone binding by activation of specific gene transcription.




This article has been cited by other articles:


Home page
 FASEB J.Home page
M. Maynadier, J.-M. Ramirez, A.-M. Cathiard, N. Platet, D. Gras, M. Gleizes, M. S. Sheikh, P. Nirde, and M. Garcia
Unliganded estrogen receptor {alpha} inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21WAF1)
FASEB J, March 1, 2008; 22(3): 671 - 681.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Duong, N. Boulle, S. Daujat, J. Chauvet, S. Bonnet, H. Neel, and V. Cavailles
Differential Regulation of Estrogen Receptor {alpha} Turnover and Transactivation by Mdm2 and Stress-Inducing Agents
Cancer Res., June 1, 2007; 67(11): 5513 - 5521.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J M W Gee, V E Shaw, S E Hiscox, R A McClelland, N K Rushmere, and R I Nicholson
Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S77 - S88.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Qi, J. Tang, M. Loesch, N. Pohl, S. Alkan, and G. Chen
p38{gamma} Mitogen-Activated Protein Kinase Integrates Signaling Crosstalk between Ras and Estrogen Receptor to Increase Breast Cancer Invasion.
Cancer Res., August 1, 2006; 66(15): 7540 - 7547.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Oxelmark, J. M. Roth, P. C. Brooks, S. E. Braunstein, R. J. Schneider, and M. J. Garabedian
The Cochaperone p23 Differentially Regulates Estrogen Receptor Target Genes and Promotes Tumor Cell Adhesion and Invasion.
Mol. Cell. Biol., July 1, 2006; 26(14): 5205 - 5213.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Sharma, N. K. Saxena, N. E. Davidson, and P. M. Vertino
Restoration of Tamoxifen Sensitivity in Estrogen Receptor-Negative Breast Cancer Cells: Tamoxifen-Bound Reactivated ER Recruits Distinctive Corepressor Complexes.
Cancer Res., June 15, 2006; 66(12): 6370 - 6378.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
F. Moll, C. Millet, D. Noel, B. Orsetti, A. Bardin, D. Katsaros, C. Jorgensen, M. Garcia, C. Theillet, P. Pujol, et al.
Chordin is underexpressed in ovarian tumors and reduces tumor cell motility
FASEB J, February 1, 2006; 20(2): 240 - 250.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. M. Jacobsen, S. A. Schittone, J. K. Richer, and K. B. Horwitz
Progesterone-Independent Effects of Human Progesterone Receptors (PRs) in Estrogen Receptor-Positive Breast Cancer: PR Isoform-Specific Gene Regulation and Tumor Biology
Mol. Endocrinol., March 1, 2005; 19(3): 574 - 587.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. Mutsuga, T. Shahar, J. G. Verbalis, C. C. Xiang, M. J. Brownstein, and H. Gainer
Regulation of Gene Expression in Magnocellular Neurons in Rat Supraoptic Nucleus during Sustained Hypoosmolality
Endocrinology, March 1, 2005; 146(3): 1254 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Paredes, C. Stove, V. Stove, F. Milanezi, V. Van Marck, L. Derycke, M. Mareel, M. Bracke, and F. Schmitt
P-Cadherin Is Up-Regulated by the Antiestrogen ICI 182,780 and Promotes Invasion of Human Breast Cancer Cells
Cancer Res., November 15, 2004; 64(22): 8309 - 8317.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
N. Mutsuga, T. Shahar, J. G. Verbalis, M. J. Brownstein, C. C. Xiang, R. F. Bonner, and H. Gainer
Selective Gene Expression in Magnocellular Neurons in Rat Supraoptic Nucleus
J. Neurosci., August 11, 2004; 24(32): 7174 - 7185.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Dutertre and C. L. Smith
Ligand-Independent Interactions of p160/Steroid Receptor Coactivators and CREB-Binding Protein (CBP) with Estrogen Receptor-{alpha}: Regulation by Phosphorylation Sites in the A/B Region Depends on Other Receptor Domains
Mol. Endocrinol., July 1, 2003; 17(7): 1296 - 1314.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. F. Su, Z. Wang, and M. J. Garabedian
Regulation of GRIP1 and CBP Coactivator Activity by Rho GDI Modulates Estrogen Receptor Transcriptional Enhancement
J. Biol. Chem., September 27, 2002; 277(40): 37037 - 37044.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. Lazennec, D. Bresson, A. Lucas, C. Chauveau, and F. Vignon
ER{beta} Inhibits Proliferation and Invasion of Breast Cancer Cells
Endocrinology, September 1, 2001; 142(9): 4120 - 4130.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society